CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 14 No. 3 3
 

Congress Denies FDA Power to Regulate Tobacco Products

By ROY S. HERBST, MD, PhD
The University of Texas
M . D. Anderson Cancer Center
Houston, Texas
| March 1, 2005

WASHINGTON-Hope that the FDA would finally gain authority to regulate tobacco products more aggressively was dashed when a House- Senate conference committee dropped the provision, which the Senate had passed as part of the 2004 Foreign Sales Corporation (FSC) tax cut bill. The legislation, which President Bush signed into law on Oct. 24, did contain a $10 billion buy-out package for tobacco farmers, that will end a federal tobacco crop quota system instituted during the Depression. The Senate passed the tobacco-regulation provision in July by a 78 to 15 vote, the first time either house had voted FDA regulatory power over the tobacco industry. The Senate's action sent the expectations of public health and anti-tobacco organizations soaring. A joint statement by four groups called the Senate vote "a giant step toward a national tobacco policy that can significantly reduce the number of children who become addicted to tobacco products and the number of people who die each year from tobacco- caused disease." However, the House version of the FSC bill did not include the tobacco regulation powers, and in the conference committee to resolve differences between the two measures, House negotiators led by Rep. Bill Thomas (R-Calif) refused to accept the Senate provision in the bill. The tobacco industry lobbied strenuously to defeat the attempt to regulate its products. Coincidentally, the Campaign for Tobacco-Free Kids released its quarterly report on the industry's contributions to federal candidates 9 days after the conference committee reported the final version of the FSC bill. It showed total donations during the 2003-2004 election cycles of $2.8 million.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

Results of Study May Effect Change in Clinical Practice for Early Lung Cancer Two phase III trials included impressive results for adjuvant chemotherapy for patients with early stage, non-small-cell lung cancer (NSCLC) that may change the course of clinical practice. The two trials compared the efficacy and safety of chemotherapy, given in combination over 12-16 weeks, with observation alone (the current standard of care) for patients with stage I or stage II disease who had surgical resection (ASCO abstract 7018 and abstract 7019). See page 5 for more details. Studies Evaluate Role of EGFR Inhibitor Positive results of a phase III randomized placebo-controlled trial of erlotinib (Tarceva) when used alone to treat patients with stage IIIB/IV NSCLC were reported at ASCO 2004. The study is the first randomized trial to confirm that erlotinib can prolong survival for patients with NSCLC for whom first or second-line treatment has failed (ASCO abstract 7022, see page 5 for more details). Two other phase III studies in which erlotinib was combined with chemotherapy regimens were reported to have shown no benefit to adding the EGF receptor inhibitor to two standard treatment protocols for NSCLC (ASCO abstracts 7010 and 7011). These other studies evaluated the use of erlotinib with chemotherapy and shared a protocol design strategy and produced similar results. Both studies enrolled patients with stage IIIB/IV NSCLC. See page 7 for a report on a subanalysis of some of these data. Drug Approvals for Lung Cancer February 2004 -Alimta (pemetrexed for injection) received approval for use in combination with cisplatin for the treatment of malignant pleural mesothelioma. See page 19 for more details. August 2004- Alimta received accelerated approval for the treatment of locally advanced or metastatic NSCLC in previously treated patients. See page 12 for more details. November 2004-Tarceva (Erlotinib) received approval as a single agent in the treatment of patients with locally advanced or metastatic NSCLC whose disease has continued to progress despite other therapies including at least one prior chemotherapy regimen. See page 5 for more details.



An Annual Review of Lung Cancer


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy